Skip to main content
Sinocelltech Group Limited logo

Sinocelltech Group Limited — Investor Relations & Filings

Ticker · 688520 ISIN · CNE100003ZL3 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 659 across all filing types
Latest filing 2022-04-26 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688520

About Sinocelltech Group Limited

https://www.sinocelltech.com/

Sinocelltech Group Limited focuses on the research, development, and commercialization of innovative biologics, including monoclonal antibodies, recombinant proteins, and vaccine candidates. The company's product pipeline addresses therapeutic areas such as oncology, autoimmune disorders, hematology, and infectious diseases. Key offerings include recombinant human coagulation factor VIII for hemophilia A and a range of biosimilars. Sinocelltech leverages an integrated technology platform encompassing early-stage discovery through to large-scale industrial production. This infrastructure supports the development of high-quality biological medicines aimed at addressing unmet medical needs through advanced protein engineering and cell line development.

Recent filings

Filing Released Lang Actions
神州细胞2021年度募集资金存放与实际使用情况专项报告及鉴证报告
Audit Report / Information Classification · 100% confidence The document is titled as a "专项审计报告" (Special Audit Report) and "募集资金存放与实际使用情况专项报告及鉴证报告" which translates to "Special Report on the Custody and Actual Use of Raised Funds and the Assurance Report." It is issued by an accounting firm (PwC) and includes detailed audit procedures and opinions on the company's use of raised funds in 2021. The document references regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange regarding the management and use of raised funds. It contains detailed financial data on the raised funds, their usage, cash management, and investment products related to idle raised funds. The document is a standalone audit/assurance report on a specific aspect of the company's financials (raised funds usage), not a full annual or interim report. It is not a mere announcement or certification but contains substantive audit findings and opinions. Therefore, it fits the category of Audit Report / Information (AR). FY 2021
2022-04-26 Chinese
神州细胞2022年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年第一季度报告' which translates to '2022 First Quarter Report'. It contains detailed financial data including consolidated and parent company balance sheets, profit and loss statements, and cash flow statements for the first quarter of 2022. The report explicitly states it is unaudited and covers the period January to March 2022. The presence of comprehensive financial statements and analysis for a period shorter than a full fiscal year clearly identifies this as an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data, not just an announcement or certification. Therefore, the correct classification is Interim / Quarterly Report (IR). Q1 2022
2022-04-26 Chinese
神州细胞2021年度内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '2021 年度内部控制审计报告' which translates to '2021 Internal Control Audit Report'. It is issued by an accounting firm (PwC) and includes audit opinions on the effectiveness of internal controls over financial reporting as of December 31, 2021. The document is a standalone audit report focusing on internal control audit results, not a full annual report or financial statement. It does not contain full financial statements or comprehensive annual report content. The length is 1721 characters, indicating it is a concise audit report rather than a full report or announcement. Therefore, it fits the category of Audit Report / Information (AR). FY 2021
2022-04-26 Chinese
独立董事候选人声明（何为）
Governance Information Classification · 95% confidence The document is a formal declaration by an independent director candidate of Beijing Shenzhou Cell Technology Group Co., Ltd. It details the candidate's qualifications, independence, compliance with relevant laws and regulations, and commitment to duties. There is no financial data, no report or announcement of financial results, no voting results, no management changes, or other typical financial or corporate filings. The document is a statement related to governance and compliance, specifically about the qualifications and independence of a board member candidate. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-04-26 Chinese
神州细胞2021年度募集资金存放与实际使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a special report on the storage and actual use of raised funds for the year 2021 by Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It details the amount of funds raised, their usage, management, and compliance with regulatory requirements. It includes financial figures related to fundraising, usage, and cash management, as well as auditor and sponsor opinions on the compliance and accuracy of the report. The document is a detailed report on the use of capital raised by the company, specifically focusing on the management and use of fundraising proceeds. This matches the description of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document is not an announcement of a report but the report itself, and it contains substantive financial data and analysis related to fundraising usage. Therefore, the appropriate classification is CAP with high confidence.
2022-04-26 Chinese
中信证券股份有限公司关于北京神州细胞生物技术集团股份公司2022年度日常关联交易预计事项的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from a sponsoring institution (中信证券股份有限公司) regarding the 2022 annual expected related party transactions of Beijing Shenzhou Cell Biotechnology Group Co., Ltd. It includes detailed descriptions of the related party transactions, their approval process by the board and independent directors, the amounts involved, the nature of the transactions, and the fairness and necessity of these transactions. The document is not a full annual report or audit report but rather a specialized verification or opinion on related party transactions for the year 2022. It does not contain full financial statements or comprehensive financial performance data. It is also not a brief announcement or a certification letter but a substantive report on a specific regulatory compliance matter related to related party transactions. This type of document fits best under the category of Regulatory Filings (RNS), which is the fallback for filings that do not neatly fit into other categories and includes compliance documents and regulatory opinions.
2022-04-26 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.